China's Pharma Tier 2 CDMOs Seek to Attain Tier 1 Status
China's Pharma Tier 2 CDMOs Seek to Attain Tier 1 Status
Attachment: A
BEIJING--September 8, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--China's Tier 2 pharmaceutical contract development and manufacturing companies (CDMOs) have the opportunity to leap to Tier 1 status as more Pharmaceutical & Biotech companies in the West outsource their services, and as China sees the benefits of its Marketing Authorization Holder (MAH) pharmaceutical regulatory system. Tier 2 CDMOs have annual revenue of up to US$500 million, while Tier 1 CDMOs have revenue of more than $US500 million.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects
- U.S. Home to Billions' Worth of 2Q ESG Project Kickoffs
- Japan Hosts $832 Million in CDMO/CMO-Related Pharma Projects
- Turner Construction Involved in More than $24 Billion Worth of U.S. Project...